The ability of tissues to heal rapidly following injury or inflammation is an important mechanism for survival in nature. However, in many instances, healing is either impaired or continues unabated leading to progressive tissue fibrosis. In the skin and internal organs progressive fibrosis can lead to a multitude of clinical conditions ranging from scarring and disfiguration, to chronic diseases such as liver disease, chronic kidney disease and heart failure (1) (2) (3) . In contrast, certain injuries result in a defective wound matrix and display failure of re-epithelialisation leading to deficient healing. This is a feature of chronic non-healing wounds, which are prominent in diabetics and in the elderly. The achievement of rapid and efficient healing without scarring and fibrosis is therefore the focus of much ongoing study.
In adults, the oral mucosa is the only tissue that demonstrates rapid healing without any discernable scar formation. Thus investigating healing in the context of oral mucosal injuries may contribute towards improved understanding of the mechanisms required to procure efficient and scar-free healing in other tissues.
In all tissues fibroblasts are considered to be the primary source of reparative matrix. In response to tissue injury they proliferate, migrate to the site of injury and differentiate into their activated form, myofibroblasts (4) (5) (6) . These myofibroblasts are then involved in wound contraction and ECM generation (7, 8) . Increased activation and proliferation of resident fibroblasts is therefore an important early step, which is central to the wound healing process. Numerous studies have shown that fibroblasts exhibit a degree of phenotypic plasticity with respect to their size, migration, proliferation, differentiation and collagen turnover (7, (9) (10) (11) . In line with this, we have previously shown that fibroblasts derived from the non-scarring oral mucosa have a distinct cellular phenotype. They demonstrate increased migration and extra-cellular matrix reorganisation as compared to other fibroblasts (12) (13) (14) . Of significance they also demonstrate a differential response to the pro-fibrotic cytokine Transforming Growth Factor-!1 (TGF-!1) as compared to normal fibroblasts (15, 16) . We have recently shown that oral fibroblasts are resistant to TGF-!1 driven myofibroblastic differentiation. Furthermore, we demonstrated that the matrix polysaccharide hyaluronan (HA) plays a pivotal role in regulating TGF-!1 driven cellular differentiation in that it facilitates fibroblast-myofibroblast transition (15) . We have also previously shown that whilst most fibroblasts proliferate when exposed to TGF-!1, fibroblasts derived from the oral mucosa demonstrate an anti-proliferative response to this cytokine (16) . HA was also found to be linked to the TGF-!1 driven proliferative response.
HA is a linear non-sulphated glycosaminoglycans which is a key component of vertebrate connective tissue matrix. It is involved in a range of cellular functions including cell-cell adhesion, migration, proliferation and differentiation and therefore plays an important role in wound healing and tissue repair (17) (18) (19) (20) (21) (22) (23) (24) . The biosynthesis of HA is regulated by three mammalian HA Synthase (HAS) isoenzymes, of which Hyaluronan Synthase 2 (HAS2) demonstrates the greatest expression in fibroblasts (15, (25) (26) (27) . It signals through interaction with several cell-surface receptors and the adhesion molecule CD44 is the best characterised of these (28) . Using a library of patient-matched oral mucosal and dermal fibroblasts, we previously demonstrated the relationship between HA generation and fibroblast-specific variation in TGF-!1-dependent proliferation (16) . Dermal fibroblasts with high levels of HA generation and high HAS2 expression proliferate in response to TGF-!1, whilst oral mucosal fibroblasts with low HAS2 expression and low levels of HA generation demonstrate an antiproliferative response to TGF-!1. Moreover, we have also shown that by altering the levels of HA generated by the fibroblasts, we can effectively modify the resultant response to TGF-!1. However, although it has been shown that HA promotes a proliferative response to TGF-!1, the mechanism through which it regulates TGF-!1 dependent responses and thereby potentially influences the fibrotic response has not yet been fully understood.
It is widely accepted that the cytokine TGF-!1 is a mediator of tissue repair and its aberrant expression is strongly implicated in progressive tissue fibrosis (29-32). Several studies have indicated that Epidermal Growth Factor (EGF) enhances the pro-fibrotic effects of TGF-!1 suggesting that it also plays an important role in progressive tissue fibrosis (33) (34) (35) (36) . In our recent studies, we have demonstrated that fibroblasts lose their ability to achieve TGF-!1 driven differentiation as they undergo cellular senescence, affecting their ability to attain appropriate wound closure and tissue repair (25) . We have shown that this age-related resistance to TGF-!1 is associated with loss of the EGF Receptor (EGF-R); and furthermore that the EGF-R is essential for signal transduction through CD44 and the MAPK/ERK signalling pathway necessary for differentiation (37) . In this study we sought to identify the mechanisms underlying the HA-dependent regulation of fibroblast proliferation; and furthermore sought to investigate if the resistance to TGF-!1 driven proliferation seen in oral mucosal fibroblasts is also related to EGF-R expression or function. Cell culture -Donor matched samples of oral mucosal and dermal fibroblasts were obtained by biopsy from consenting adults undergoing routine minor surgery, and ethical approval for the biopsies was obtained from the South East Wales Research Ethics Committee. The cells were isolated as described previously (12, 15) and cultured in Dulbecco's modified Eagle's medium and F-12 medium containing 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin supplemented with 10% fetal calf serum (FCS) (Biologic Industries Ltd., Cumbernauld, UK). The cells were maintained at 37 °C in a humidified incubator in an atmosphere of 5% CO2, and fresh growth medium was added to the cells every 3-4 days until confluent. The cells were incubated in serum-free medium for 48 hours before use in experiments, and all experiments were done under serum-free conditions unless otherwise stated. All experiments were undertaken using cells at passage 6-10 and performed on confluent cultures except for those examining proliferation. These experiments used sub-confluent cells to allow for cell growth. figure legends) . The medium was then discarded and the cells washed repeatedly with PBS containing 1 mM Thymidine prior to fixing with 500 µl of 5% trichloracetic acid containing 1 mM Thymidine at 4 °C for 1 hour. The cell layer was extracted by incubation with 1 ml of 0.1 M NaOH at 20 °C for 24 hours and neutralised with 0.1 M HCl. The radioactivity was determined by ! counting on a Packard Tri-Carb 1900 liquid scintillation analyser and the results represented as disintegrations per minute (dpm).
METHODS

Materials -
Analysis of Cell Proliferation -
Reverse Transcription (RT) and Quantitative PCR (QPCR) -RT and QPCR was used to assess CD44, HAS2, EGF and EGF-Receptor mRNA expression in oral mucosal and dermal fibroblasts. The cells were grown in 35 mm dishes and washed with PBS prior to lysis with tri-reagent and RNA purification according to the manufacturer's protocol. Reverse transcription was performed using the High Capacity cDNA Reverse Transcription Kits according to the manufacturer's protocol (Applied Biosystems). This uses the random primer method for initiating cDNA synthesis. As a negative control RT was performed with by guest on June 27, 2017 http://www.jbc.org/ Downloaded from sterile H2O replacing the RNA sample. QPCR was performed as in our previous manuscripts using the 7900HT fast real time PCR system from Applied Biosystems (37) .
Small Interfering RNA (siRNA) TransfectionTransient transfection of fibroblasts was performed with specific siRNA nucleotides (Applied Biosystems) targeting CD44. Transfection was performed in 35 mm dishes using Lipofectamine 2000 transfection reagent (Invitrogen) in accordance with the manufacturer's protocol as described in our previous manuscript (37) . As a control, cells were transfected with negative control siRNA (a scrambled sequence that bears no homology to the human genome) (Applied Biosystems).
Over-expression of HAS2 -HAS2 open reading frame (ORF) (25, 37) was inserted into the vector pCR3.1 using a standard ligation reaction with Promega T4 DNA Ligase. Amplification of the cloned vector was performed via bacterial transformation (JM109 competent Escheria coli, Promega) as described previously (37) . Transient transfection was performed with the aid of Nucleofector technology (Amaxa Biosystems) in accordance with the manufacturer's protocol for transfection of primary mammalian fibroblasts (37) . The cells were transfected either with HAS2-pCR3.1 or pCR3.1 (Mock Transfected), and were incubate for 24 hours in serum-free medium prior to experimentation. pmaxGFP transfection was performed in parallel and used to calculate transfection efficiency (41.3% following 48 hours and 39.1% following 96 hours).
Simultaneous over-expression of HAS2 and CD44 knockdown -In one of the experiments (figure 4) HAS2-pCR3.1 and CD44 siRNA were transfected simultaneously into oral mucosal fibroblasts. Nucleofector technology as described above was used for transfection of both HAS2-pCR3.1 and CD44 siRNA. The final concentration of CD44 siRNA used was 30 nM, and 1 µg of HAS2-pCR3.1 DNA was used as in previous experiments. Mock transfection with pCR3.1 and transfection with scrambled siRNA were performed as controls. RT and QPCR were performed to assess over-expression of HAS2 and CD44 knockdown.
Immunoblotting/Western Analysis -Western blot analysis was used to assess expression of phosphorylated ERK1 and ERK2 (p44/42). Cells were grown to confluence in 35mm dishes and western blot analysis was carried out as described in our previous manuscripts (37) Friedman Test was used for global comparison of different groups, followed by the Wilcoxon Signed-Rank Test for sub-group analysis. All data were analysed using the software (SPSS 14.0 Chicago, IL, USA) and P < 0.05 was considered significant.
RESULTS
TGF-!1
dependent proliferation in fibroblasts is mediated through the HA receptor, CD44; whereas the TGF-!1 dependent anti-proliferative response is independent of CD44. The involvement of the principal HA receptor, CD44, in the regulation of TGF-!1 dependent proliferation in dermal fibroblasts was assessed by the use of siRNA to downregulate CD44 levels (figure 1). Figure 1A demonstrates the successful knockdown of CD44 expression in dermal fibroblasts following transient transfection with CD44 siRNA, as compared to dermal fibroblasts transfected with the scrambled control. In parallel experiments, the alamarBlue TM assay (figure 1B) and the 3 H-Thymidine assay (figure 1C) were used to assess the effect of CD44 knockdown on TGF-!1 dependent proliferation in dermal fibroblasts. As we have previously demonstrated (16) , in the nontransfected cells and the cells transfected with scrambled controls, stimulation with TGF-!1 promotes proliferation in dermal fibroblasts. However, down-regulation of CD44 in these cells resulted in loss of TGF-!1 dependent proliferation and an anti-proliferative response to TGF-!1 ensued.
In oral mucosal fibroblasts, TGF-!1 normally promotes an anti-proliferative response (16) . The involvement of CD44 in regulation of the TGF-!1 driven anti-proliferative response in these cells was also assessed using siRNA to knockdown CD44 levels (figure 2). Despite potent down-regulation of CD44 expression (figure 2A), there was no effect on the TGF-!1 driven anti-proliferative response in oral cells using either the alamarBlue TM assay (figure 2B) or the 3 H-Thymidine assay (figure 2C).
In our previous studies, the differential effects of TGF-!1 on dermal and oral fibroblasts were shown to be related to the levels of HA generated by these cells (16, 38) . In this study, the central role of HAS2 in the regulation of proliferation in fibroblasts was investigated using HAS2 over-expression vectors (figure 3). HAS2 over-expression in oral fibroblasts was initially confirmed by using RT and QPCR ( figure 3A) . Subsequent assessment of cell growth following HAS2 over-expression demonstrated that the oral fibroblasts then behaved like dermal fibroblasts and demonstrated a proliferative response to TGF-!1 ( figure 3B and 3C) . Thereafter, the involvement of CD44 in TGF-!1 driven proliferation in HAS2 transfected oral fibroblasts was assessed. Initially successful over-expression of HAS2 and knockdown of CD44 was again confirmed by RT and QPCR (figure 4A and 4B respectively). Following this, the 3 H-Thymidine assay was used to assess the effects on TGF-!1 dependent cell proliferation ( Figure 4C ). The results revealed that oral fibroblasts transfected with mock or scrambled controls have an anti-proliferative response to TGF-!1 as expected. In confirmation of the results shown in figure 3B and 3C, oral fibroblasts transfected with the HAS2 over-expression vector demonstrated a proliferative response to TGF-!1. Of significance, following combined transfection with HAS2 and CD44 siRNA, the oral fibroblasts demonstrated an anti-proliferative to response to TGF-!1 indicating the important regulatory role of CD44 in this system.
EGF and its receptor (EGF-R) are essential for
TGF-!1/HA/CD44 dependent proliferation in dermal fibroblasts and HAS2 over-expressed oral fibroblasts. We have previously shown that resistance to TGF-!1 driven fibroblast differentiation associated with cellular senescence was associated with loss of the EGF-R (37).
Comparison of EGF-R and EGF expression was therefore performed in both oral and mucosal fibroblast populations using RT/QPCR to investigate their potential role in resistance to TGF-!1 driven proliferation ( figure 5A and 5B respectively). However, both the scarring and non-scarring fibroblast phenotypes expressed EGF-R (figure 5A) and EGF (figure 5B) at similar levels. Of note, TGF-!1 stimulation is shown to increase EGF mRNA expression in both fibroblast phenotypes (figure 5B).
To investigate the possible participation of either EGF-R or EGF in TGF-!1 dependent proliferation, dermal cells were treated with TGF-!1 in the presence of either the EGF-R inhibitor (AG1478) or an EGF antibody (figures 6A and 6B respectively), and cell proliferation was assessed using the 3 HThymidine assay. Addition of either the chemical inhibitor (AG1478) or anti-EGF neutralising antibodies appeared to inhibit TGF-!1 driven proliferation in dermal fibroblasts. Furthermore, inhibiting either EGF or its antibody was also shown to inhibit the TGF-!1 driven proliferative response in oral HAS2 transfected cells (figure 7).
In the presence of HA, the EGF-R and CD44 appear to co-localise. Signalling mediated by the EGF-R has been shown to be diversified by interaction with a number of proteins including the HA receptor, CD44 (37, 39) . These interactions have been shown to have fundamental importance in subsequent cell signalling cascades (40, 41) . Given the decisive role played by both EGF-R and CD44 in TGF-!1 driven proliferation, we sought to investigate the potential for interaction between these two proteins in our system using immunocytochemistry to stain for these proteins ( figure 8 ). The results demonstrated increased yellow colour depicted at the cell periphery in the images with HAS2 over-expression and TGF-!1 stimulation, suggesting increased EGF-R and CD44 co-localisation in these circumstances. In comparison co-localisation was not clearly apparent in either the mock transfected oral fibroblasts or in the unstimulated HAS2 transfected oral fibroblasts.
TGF-!1/HA/CD44-dependent fibroblast proliferation signals through the MAPK/ERK pathway. The classical signalling pathway for TGF-!1 involves the Smad family of transcriptional proteins (42) . However, several studies have shown that TGF-!1 can also signal in a Smadindependent fashion, recruiting pathways such as the MAPK pathway (42) . In a recent paper we have demonstrated the importance of MAPK/ERK signalling in TGF-!1 driven phenotypic activation of fibroblasts (37) . We have therefore investigated a possible role for ERK signalling in TGF-!1 driven proliferation using the chemical ERK inhibitor PD98059. We initially showed the importance of ERK signalling in TGF-!1 driven proliferation in dermal fibroblasts, as addition of the ERK inhibitor was shown to attenuate the proliferative response (figure 9A). We then showed that ERK signalling is also essential for TGF-!1 driven proliferation in HAS2 over-expressed oral fibroblasts (figure 9B).
In light of the above results, we subsequently assessed the ability of the two fibroblast populations to activate ERK1 and ERK2 in response to TGF-!1 stimulation (figure 10). Western blot analysis in dermal fibroblasts demonstrated increased ERK1/2 phosphorylation at an early time point of 20 minutes following administration of TGF-!1. ERK1/2 phosphorylation then returned to basal levels by 40 minutes. In dermal fibroblasts, a second peak of ERK1/2 activation was also demonstrated at the later time points of 1 to 3 hours post TGF-!1 stimulation. In comparison, western blot analysis in oral fibroblasts also demonstrated increased ERK1/2 activation at the early time point of 10 minutes post TGF-!1 stimulation. In contrast to dermal cells however, oral fibroblasts did not demonstrate a second peak of ERK1/2 activation. The effect of inhibiting EGF-R activation by using the AG1478 compound on ERK1/2 activation demonstrated loss of both early and late ERK1/2 activation indicating the importance of TGF-!1 dependent EGFR activation in MAPK/ERK signalling. These results were quantified and confirmed using scanning densitometry (figure 10B). We then investigated the effects of HAS2 overexpression in oral fibroblasts on ERK1/2 signalling (figure 11). The control or mocktransfected oral fibroblasts showed only early ERK1/2 activation at 10 minutes following TGF-!1 stimulation as previous. However, oral fibroblasts transfected with the HAS2 over-expression vector also demonstrated a second wave of ERK1/2 activation at 3 hours post TGF-!1 stimulation, similar to the pattern of ERK activation seen in dermal fibroblasts. Furthermore, the incubation of HAS2 transfected oral cells with the EGF-R inhbitor (AG1478) again showed loss of both peaks of ERK1/2 activation. These results have also been quantified and confirmed by the use of scanning densitometry (figure 11B). 
DISCUSSION
Fibroblast proliferation is a process central to tissue repair, and factors that govern fibroblast proliferation play an important role in determining wound-healing outcomes. The cytokine TGF-!1 is a known mediator of fibroblast proliferation, and several reports have established that increased expression of this cytokine directly correlates with progression of tissue fibrosis (31, 32, 43, 44) . A better understanding of factors that are involved in the regulation of TGF-!1 mediated fibroblast proliferation are therefore crucial in determining the pathogenic mechanisms that lead to either impaired or excessive healing. During the search for regulators of fibroblast proliferation, hyaluronan was identified as a prime candidate. Many researchers have shown its involvement in processes fundamental to tissue repair (45) (46) (47) . Our previous research demonstrated its central role in the regulation of TGF-!1 dependent fibroblast to myofibroblast differentiation (38, 48) . We then proceeded to show that it also plays a key role in determination of fibroblast proliferative response to TGF-!1 (16) . Notably, we showed that oral fibroblasts, with a non-scarring phenotype, generate low HA levels and show an inhibitory growth response to TGF-!1; whilst dermal fibroblasts, that can produce scarring, generate larger amounts of HA and show an accelerated growth response to this cytokine. Furthermore, we showed that the increased HA generation in dermal fibroblasts is causally related to TGF-!1 driven proliferation in these cells, and that inhibiting HA synthesis in dermal fibroblasts resulted in an anti-proliferative response to TGF-!1. Thus we have previously demonstrated that modulating HA levels in dermal fibroblasts alters their function to behave in a manner similar to non-scarring oral mucosal fibroblasts. In this study, we provide mechanistic insights into how HA can modify TGF-!1 dependent proliferation in fibroblasts, and thereby present a number of amenable targets for the control of fibroblast proliferation and ultimately for the regulation of tissue repair.
HA effects its biological responses in part through its interaction with a number of cellsurface receptors (49, 50) . In this work, we initially sought to determine if the principal HA receptor, CD44, was involved in either the TGF-!1 driven proliferative or antiproliferative responses in fibroblasts. The results indicated that knockdown of CD44 in the HA-rich dermal fibroblasts had a profound effect on TGF-!1 driven proliferation, leading to a complete reversal of this response with an ensuing anti-proliferative response. Meanwhile CD44 knockdown in oral fibroblasts did not change the TGF-!1 response. These results are in accordance with previous research from our group demonstrating that both HA and CD44 promote the pro-fibrotic actions of TGF-!1 (15, 16, 48) . To further verify this data, we over-expressed HAS2 in the non-scarring oral mucosal fibroblast phenotype. We have previously shown that the HAS2 overexpression vector increases HA production in fibroblasts thus generating a HA-rich environment similar to that seen in dermal fibroblasts (25) . This HA-rich environment subsequently led to a proliferative response to TGF-!1 in the oral cells, similar to the response seen in the scar-forming dermal fibroblasts. Furthermore, once the oral cells were in the presence of a HA-rich environment, CD44 once again became crucial in mediating this response. These results again assert that the levels of HA are decisive in determining the outcome of TGF-!1 dependent cell responses. It is not known whether the observed changes are due to the presence of HA bound to HA Synthase, secreted HA or increased HA actually bound to CD44; however the data suggests that it is HA-CD44 binding that is necessary for TGF-!1 driven proliferation, as the presence of HA as well as CD44 was necessary for this response to occur. Hence this data suggests that in the presence of a HA-rich matrix, HA binds to CD44 and alters a fibroblast's proliferative response to TGF-!1, whereas in a non HA-rich environment, TGF-!1 mediates its responses through other CD44 independent pathways such as the Smad pathway (16) . These results are consistent with our previous data showing that inhibition of HA synthesis in dermal fibroblasts results in an antiproliferative response to TGF-!1 (16) .
The EGF receptor is a transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors (51). It binds EGF as well as several other peptide growth factors and is involved in the activation of multiple signal transduction pathways including MAPK (52) . As such it is known to be a robust regulator of cellular processes such as proliferation (53) . Signalling mediated by the EGFR is diversified by its interaction with a number of non-ErbB proteins, and the CD44 receptor has been reported to be one of these proteins (39) . A number of reports have implicated EGF and its receptor in fibroproliferative processes in humans and in animal models of lung and kidney disease (35, 36, 54) . Furthermore, some studies have demonstrated that synergistic action of EGF/EGF-R and TGF-!1 can induce epithelial to mesenchymal transition, the process through which epithelial cells may transform into fibroblasts and promote fibrosis (35) . Our group has previously demonstrated that EGF and EGF-R signalling through the MAPK/ERK pathway are essential for HAmediated TGF-!1-driven fibroblast to myofibroblast differentiation; and loss of either HA, EGF or EGF-R results in failure of fibroblast differentiation and suboptimal wound closure (37) . In this study, we have investigated whether EGF and its receptor are also involved in TGF-!1 dependent fibroblast proliferation. The results demonstrated that whilst EGF and its receptor are both equally expressed in scarring and non-scarring fibroblast phenotypes, blocking either EGF or EGF-R activity effectively attenuates TGF-!1/HA/CD44 dependent proliferation in the dermal cells as well as in the HA-rich oral mucosal cells. Thus indicating that EGF and its receptor are both important targets for the manipulation of TGF-!1 driven fibroblast proliferation in a HA rich environment.
As described above, CD44 can function as a co-receptor, physically co-localising with other membrane bound proteins resulting in modulation of intracellular signal transduction pathways and facilitating the formation of specialised signalling complexes (39) . In light of previous reports indicating interactions between CD44 and EGF-R in other cell types, we sought to determine if this interaction occurs in our system. We have previously reported that in dermal fibroblasts, CD44 and EGF-R co-localisation occurs following TGF-!1 stimulation (37). Here we report that in oral fibroblasts EGF-R and CD44 colocalisation only occurs in HAS2-transfected cells stimulated with TGF-!1. This data indicates that the presence of HA is required for CD44/EGF-R coupling following TGF-!1 stimulation. This data is consistent with research performed in the cancer field that demonstrates that HA promotes clustering of EGF-R and CD44 forming a functional unit in the cell membrane of tumour cells (55) . Many studies have shown that HA itself is able to bind and activate the EGF-R and thus potentiate downstream signalling processes (40) . However in our system this does not appear to be the case as increasing HA levels through over-expression of HAS2 alone is insufficient to drive EGF-R-CD44 coupling, as TGF-!1 stimulation is also essential. We have also shown that TGF-!1 is required for EGF induction in both fibroblast phenotypes. Furthermore, use of EGF blocking antibodies in HAS2 transfected oral cells eliminates the TGF-!1 driven proliferative response. This indicates that the proliferative response is also EGF dependent and that HA does not substitute as a ligand for EGF in EGF/EGF-R binding. Taken together this data suggests that TGF-!1 mediated induction of EGF may be necessary to promote CD44/EGF-R coupling, and EGF/EGF-R as well as HA/CD44 binding is necessary to drive the CD44/EGF-R interaction.
In our previous work we have shown that both oral and dermal fibroblast populations demonstrate strong activation of the Smad signalling pathway in response to TGF-!1 (16) . In addition, there was a critical role for the involvement of Smad3 in the regulation of both the proliferative response in dermal fibroblasts and the anti-proliferative response in oral fibroblasts, suggesting that synergistic activity of Smad and other signalling intermediates dictate the final functional outcome of TGF-ß1 stimulation. It is well known that TGF-!1 can also induce activation of the MAP Kinase signalling pathway, and several studies have proposed a contributory role of MAPK/ERK signalling in promotion of the fibrotic response (56, 57) . We therefore sought to examine the potential involvement of MAPK/ERK signalling in TGF-!1 mediated proliferation in fibroblasts. The results reported here illustrate that inhibition of ERK1/2 activation significantly attenuated TGF-!1 driven proliferation in both dermal by guest on June 27, 2017 http://www.jbc.org/ Downloaded from fibroblasts and in HA-rich oral mucosal fibroblasts. Comparison of ERK1/2 signalling in the two fibroblast populations demonstrated that in dermal fibroblasts, TGF-!1 stimulation led to two peaks of ERK1/2 activation, whilst oral fibroblasts only demonstrated early ERK1/2 phosphorylation in response to TGF-!1. Subsequent over-expression of HAS2 in oral fibroblasts however negated the demonstrated differences in ERK1/2 signalling between the two fibroblast phenotypes. Both peaks of ERK1/2 activation appear to be dependent on a functional EGF-R. However our results suggest that it is the late ERK1/2 activation that is HA and CD44 dependent and leads to TGF-!1-driven proliferation, whereas the function of the early wave of ERK1/2 activation is not clear. Combining this data with our previous work we propose that in fibroblasts with a HA-rich matrix, TGF-!1 stimulation further increases HA levels (15, 16) and promotes the following responses: Firstly it induces Smad3 activation (which has also been shown to be central to up-regulation of HAS2 and therefore increased HA levels) (37) . In addition, it increases EGF levels, which binds to the EGFReceptor and subsequently promotes early ERK1/2 activation the functional significance of which remains unclear. Secondly, the increased HA levels enhance HA-CD44 binding and the increased EGF binds to the EGF-R. Binding of these two ligands to their receptors promotes coupling of some of the EGF-R with the CD44 receptors and this promotes late ERK1/2 activation, which is then necessary to promote proliferation. In a non HA-rich environment, Smad3 activation and only early ERK1/2 activation occurs and this is associated with an anti-proliferative response to TGF-!1. Whilst this model has many similarities to the model proposed for TGF-!1-dependent fibroblast differentiation, a number of key differences exist. Firstly, Smad3 is the principal receptor regulated Smad that is essential for TGF-!1-dependent fibroblast proliferation whereas Smad2 was shown to be vital to fibroblast differentiation. Secondly, interaction between the Smad and MAP Kinase pathway is likely necessary for TGF-!1-dependent proliferation as discussed below. Furthermore, in the model proposed here late activation of ERK1/2 is shown to be vital for TGF-!1-dependent proliferation to take place. In contrast, only early ERK1/2 activation appears to be necessary to induce cell differentiation (37) .
Proteins from the MAP Kinase pathway have been shown to modify the outcome of Smad signalling through several means. They are capable of altering phosphorylation of the Smads (58) . However, this is unlikely to occur in our system as we have previously shown that Smad phosphorylation is similar in both fibroblast phenotypes. They may serve to regulate the capacity of Smad proteins to transolocate to the nucleus (59). They are also capable of physically interacting with transcription factors, thus regulating transcription of Smad target proteins in the nucleus (60,61). Further investigation is therefore required to elucidate potential interaction between the MAPK/Smad pathways, and to determine signalling events downstream of Smad3 and ERK1/2 phosphorylation to delineate the kinetics involved in the regulation of fibroblast proliferation by TGF-!1.
The mechanisms that control the transition between scar-free tissue repair and fibrosis are complex and not well understood. Our study provides mechanistic insights into this process. The data presented here extends the findings from our previous work that demonstrate the important regulatory role of a HA rich pericellular matrix in the coordination of TGF-!1 dependent fibroblast proliferation (16) . Using our previous reports together with our current findings, we propose that stimulation of proliferation in response to TGF-!1 requires a HA-rich matrix as well as functionality of CD44, EGF and EGF-R. Our proposed model of the relationship between TGF-ß, HA and fibroblast proliferative responses is illustrated in figure 12 . In this model HA facilitates TGF-!1 dependent fibroblast proliferation through promoting interaction between the CD44 and EGF receptor. This then promotes specific intracellular signal transduction through the MAPK/ERK pathway with acts in a complementary manner to the Smad pathway resulting in cell proliferation.
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Engel [A] CD44 mRNA expression: Dermal fibroblasts were transfected with CD44 or negative control (scrambled) siRNA and incubated for 24 hours. To confirm CD44 knockdown, mRNA extraction was carried out and CD44 mRNA expression was assessed by RT-QPCR. Ribosomal RNA was used as an endogenous control, and gene expression was assessed relative to the scrambled samples. The comparative C T method was used for relative quantification of gene expression and the results expressed as box plots. For each box plot, the box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Wilcoxon Signed-Rank Test and the results are representative of three experiments.
[B] Alamar Blue Proliferation assay: In parallel experiments, the effect of CD44 knockdown on TGF-!1 driven proliferation in dermal fibroblasts was assessed using Alamar Blue TM assay (as described in methods). As above, the siRNA's were incubated with the cells in serum-free medium for 24 hours. Subsequently 10ng/ml TGF-!1 was incubated with the cells for a further 24 hours prior to analysis. The results are expressed as the mean ± standard error for three experiments.
[C]
3 H-Thymidine Proliferation assay: The effect of CD44 knockdown on TGF-!1 driven proliferation in dermal fibroblasts was also assessed using 3 H-Thymidine assay (as described in methods). As above, the siRNA's were incubated with the cells in serum-free medium for 24 hours. Subsequently 10ng/ml TGF-!1 was incubated with the cells for a further 24 hours prior to analysis. The results are expressed as box plots. For each box plot, the box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Friedman test followed by the Wilcoxon Signed-Rank Test and statistical significance was taken as P < 0.05. The results are representative of three experiments. [A] CD44 mRNA expression: Oral mucosal fibroblasts were transfected with CD44 or negative control (scrambled) siRNA and incubated for 24 hours. To confirm CD44 knockdown, mRNA extraction was carried out and CD44 mRNA expression was assessed by RT-QPCR. Ribosomal RNA was used as an endogenous control, and gene expression was assessed relative to the scrambled samples. The comparative C T method was used for relative quantification of gene expression and the results expressed as box plots. For each box plot, the box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Wilcoxon Signed-Rank Test and the results are representative of three experiments.
[B] Alamar Blue Proliferation assay: In parallel experiments, the effect of CD44 knockdown on the TGF-!1 driven anti-proliferative response in oral fibroblasts was assessed using Alamar Blue TM assay (as described in methods). As above, the siRNA's were incubated with the cells in serum-free by guest on June 27, 2017 http://www.jbc.org/ Downloaded from medium for 24 hours. Subsequently 10ng/ml TGF-!1 was incubated with the cells for a further 24 hours prior to analysis. The results are expressed as the mean ± standard error for three experiments.
3 H-Thymidine Proliferation assay: The effect of CD44 knockdown on TGF-!1 driven proliferation in oral fibroblasts was also assessed using 3 H-Thymidine assay (as described in methods). As above, the siRNA's were incubated with the cells in serum-free medium for 24 hours. Subsequently 10ng/ml TGF-!1 was incubated with the cells for a further 24 hours prior to analysis. The results are expressed as box plots. For each box plot, the box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Friedman test followed by the Wilcoxon Signed-Rank Test and statistical significance was taken as P < 0.05. The results are representative of three experiments. [A] HAS2 expression mRNA expression: Oral mucosal fibroblasts were transfected with either HAS2-pCR3.1 (HAS2 transfected) or PCR3.1 alone (Mock transfected) and incubated for 24 hours. The medium was then replaced with serum-free medium for another 24 hours before incubating the cells with either 10ng/ml TGF-!1 or unstimulated medium (control) for a further 24 hours. Total mRNA was then extracted and RT-QPCR was performed to confirm HAS2 over-expression. Ribosomal RNA was used as an endogenous control and gene expression was assessed relative to the control-Mock Transfected cells. The comparative CT method was used for relative quantification of gene expression and the results are represented as the mean ± standard error for three experiments.
[B] Alamar Blue TM Proliferation assay following HAS2 over-expression: In parallel experiments oral mucosal fibroblasts transfected with either pCR3.1 (mock transfected) or HAS2-pCR3.1 (HAS2 transfected) were stimulated with either 10ng/ml TGF-!1 or unstimulated medium (control) for 24 hours, and the Alamar Blue TM assay was used to assess fibroblast proliferation (as described in methods). The results are expressed as the mean ± standard error for three experiments.
3 H-Thymidine Proliferation assay following HAS2 over-expression: Oral mucosal fibroblasts transfected with either pCR3.1 (mock transfected) or HAS2-pCR3.1 (HAS2 transfected) were stimulated with either 10ng/ml TGF-!1 or unstimulated medium (control) for 24 hours, and the 3 HThymidine assay was used to assess fibroblast proliferation (as described in methods). The results are expressed as the median ± IQR of three experiments. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Friedman test followed by the Wilcoxon Signed-Rank Test and statistical significance was taken as P < 0.05. Oral mucosal fibroblasts were co-transfected with pCR3.1 and either CD44 siRNA or scrambled siRNA (MOCK TRANSFECTED). Alternatively oral fibroblasts were co-transfected with HAS2-pCR3.1 and either CD44 siRNA or scrambled siRNA (HAS2 TRANSFECTED). The cells were then incubated in serum-free medium for 24 hours. They were subsequently either incubated with 10ng/ml TGF!1 or unstimulated medium (control) for a further 24 hours. Analyses were then performed to [A] confirm up-regulation of HAS2 expression, [B] to confirm down-regulation of CD44 expression and [C] to assess effect of HAS2 over-expression and CD44 down-regulation on TGF-!1 driven proliferation. mRNA expression of HAS2 and CD44 was assessed using RT-QPCR.
3 H-Thymidine assay was used to assess proliferation (as described in the methods). In performed using the Friedman test followed by the Wilcoxon Signed-Rank Test and statistical significance was taken as P < 0.05.
Figure 5. Expression of [A] EGF-Receptor and [B] EGF in dermal and oral fibroblasts.
Dermal and oral mucosal fibroblasts were grown in culture as described in the methods. They were growth arrested by incubation in serum-free medium and then either incubated in medium containing 10ng/ml TGF!1 or unstimulated medium for 24 hours. Total mRNA was extracted and mRNA expression of EGF-Receptor [A] and EGF [B] were assessed using RT-QPCR. Ribosomal RNA was used as an endogenous control and the comparative CT method was used for relative quantification of gene expression. The results are represented as the mean ± standard error and are representative of three experiments. Statistical analysis was performed using the Paired students t Test and statistical significance was taken as P < 0.05. [A] Sub-confluent monolayers of dermal fibroblasts were growth-arrested in serum-free for 48 hours. The cells were then incubated with either serum-free medium alone (control), serum-free medium containing 10 ng/ml TGF-!1, serum-free medium containing EGF-Receptor Inhibitor AG1471 (10µM) alone or serum-free medium containing 10ng/ml TGF!1 and EGF-Receptor Inhibitor AG1471 (10µM). The incubations were continued for a further 24 hours and analysis of cell growth was performed using the 3 H-Thymidine assay (as described in methods). The results are expressed as the median ± IQR of three experiments. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Friedman test followed by the Wilcoxon Signed-Rank Test and statistical significance was taken as P < 0.05.
[B] Sub-confluent monolayers of dermal fibroblasts were growth-arrested in serum-free for 48 hours. The cells were then incubated with either serum-free medium alone (control), serum-free medium containing 10 ng/ml TGF-!1, serum-free medium containing 10µg/ml anti-EGF antibody or serumfree medium containing 10ng/ml TGF-!1 and 10µg/ml anti-EGF antibody. The incubations were continued for a further 24 hours and analysis of cell growth was performed using the 3 H-Thymidine assay (as described in methods). The results are expressed as the median ± IQR of three experiments. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Friedman test followed by the Wilcoxon Signed-Rank Test and statistical significance was taken as P < 0.05. Oral mucosal fibroblasts were transfected with HAS2-pCR3.1 and incubated for 24 hours. The medium was then replaced with serum-free medium for another 24 hours before incubating the cells with either unstimulated medium (control), medium containing 10ng/ml TGF-!1, medium containing 10µg/ml anti-EGF antibody, medium containing 10ng/ml TGF-!1 and 10µg/ml anti-EGF antibody, medium containing 10µM of the EGF-Receptor Inhibitor AG1471 or medium containing 10ng/ml TGF-!1 and 10µM of the EGF-Receptor Inhibitor AG1471. The incubations were continued for a further 24 hours and analysis of cell growth was subsequently performed using the Alamar Blue Oral mucosal fibroblasts were transfected with either HAS2-pCR3.1 (HAS2 transfected) or PCR3.1 alone (Mock transfected) and incubated for 24 hours. The medium was then replaced with serum-free medium for another 24 hours before incubating the cells with either 10ng/ml TGF-!1 or unstimulated medium (control) for a further 24 hours. The cells were then fixed and the expression of CD44 (red) and EGF-Receptor (green) were examined by immunocytochemistry and their association examined by merging individual images (yellow). DAPI staining was used to visualise nuclei (blue). Original magnification was x 400. [A] Sub-confluent monolayers of dermal fibroblasts were growth-arrested in serum-free medium for 48 hours. The cells were then incubated with either serum-free medium alone, serum-free medium containing 10ng/ml TGF-!1, serum-free medium containing 10µM of the ERK Inhibitor PD98059 or serum-free medium containing both 10ng/ml TGF-!1 and 10µM of the ERK Inhibitor PD98059. The incubations were continued for a further 24 hours and analysis of cell growth was performed using the 3 H-Thymidine assay (as described in methods). The results are expressed as the median ± IQR of three experiments. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Friedman test followed by the Wilcoxon Signed-Rank Test and statistical significance was taken as P < 0.05.
[B] Sub-confluent monolayers of oral fibroblasts were transfected with HAS2-pCR3.1 and incubated for 24 hours. The cells were then incubated with either serum-free medium alone, serum-free medium containing 10ng/ml TGF-!1, serum-free medium containing 10µM of the ERK Inhibitor PD98059 or serum-free medium containing both 10ng/ml TGF-!1 and 10µM of the ERK Inhibitor PD98059. The incubations were continued for a further 24 hours and analysis of cell growth was performed using the 3 H-Thymidine assay (as described in methods). The results are expressed as the median ± IQR of three experiments. For each box plot, median values are represented by the line within the box. The box represents 50% of the values (the 25th and 75th centiles), with the bars presenting the highest and lowest values. Statistical analysis was performed using the Friedman test followed by the Wilcoxon Signed-Rank Test and statistical significance was taken as P < 0.05. [A] Confluent monolayers of dermal and oral fibroblasts were growth arrested in serum-free medium for 48 hours. Subsequently they were incubated with 10ng/ml TGF-!1 for up to 3 hours and phosphorylation of ERK 1/2 proteins were assessed by Western Blot analysis at the indicated times. Phosphorylation of ERK1/2 in dermal fibroblasts following incubation with 10ng/ml of the EGFReceptor Inhibitor AG1471 was also assessed. Western Blot analysis for GAPDH was performed to ensure equal loading of protein samples.
[B] Following scanning densitometry, alteration in phosphorylated ERK1/2 expression were corrected for the expression of GAPDH and represented as the mean ± S.D. of three separate experiments. Statistical analysis was performed using the paired students t test and statistical significance was taken as P < 0.05. [A] Oral mucosal fibroblasts were transfected with either HAS2-pCR3.1 (HAS2 transfected) or PCR3.1 alone (Mock transfected) and incubated for 24 hours. The medium was then replaced with serum-free medium for another 24 hours before incubating the cells with 10ng/ml TGF-!1 for up to 3 hours. Phosphorylation of ERK 1/2 proteins were assessed by Western Blot analysis at the indicated times. Phosphorylation of ERK1/2 in HAS2 transfected oral fibroblasts following incubation with 10ng/ml of the EGF-Receptor Inhibitor AG1471 was also assessed. Western Blot analysis for GAPDH was performed to ensure equal loading of protein samples.
[B] Following scanning densitometry, alteration in phosphorylated ERK1/2 expression were corrected for the expression of GAPDH and represented as the mean ± S.D. of three separate experiments. Statistical analysis was performed using the Paired students t test and statistical significance was taken as P < 0.05. 
